CDx development
Illumina Adds CDx Indication to European TruSight Oncology Test for NTRK Gene Fusion Detection
The CDx pan-cancer indication will allow the identification of patients with NTRK gene fusions who may benefit from therapy with Bayer's Vitrakvi (larotrectinib).
Avalon GloboCare, Lu Daopei Hematology Institute Partner to Develop Cell Therapy CDx
The deal, which is subject to negotiation, will help Avalon create diagnostics for personalizing its current and future cell immunotherapy programs.
Illumina, Janssen Biotech Form Strategic Partnership to Develop Precision Medicines
The collaboration aims to utilize the sequencing giant's data analytics platforms and lab services to speed up the development of personalized therapies.
FDA Approves Thermo Fisher Scientific Oncomine Dx Assay as CDx for Janssen Lung Cancer Drug
The Oncomine Dx Target Test will be used as a companion diagnostic to identify NSCLC patients whose tumors carry EGFR Exon20-insertion mutations.
FDA Approves Janssen's Rybrevant, Guardant360 CDx for EGFR Exon 20-Mutated NSCLC
The agency approved amivantamab for non-small cell lung cancer patients harboring EGFR exon 20 mutations, as detected by Guardant Health's blood-based test.